Document:

EX-10.17

 Exhibit 10.17 

CONFIDENTIAL TREATMENT REQUESTED 

SEVENTH AMENDMENT TO LICENSE AGREEMENT 

THIS SEVENTH AMENDMENT TO LICENSE AGREEMENT (this “Seventh Amendment”), effective March 31, 2011, is by and
among: 
 Angiotech Pharmaceuticals (US), Inc., a corporation organized and existing under the laws of the State of Washington, with
principal offices at North Bend, WA (“Angiotech US”); 
 Angiodevice International GmbH, a corporation organized and
existing under the laws of the Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (“Angiodevice”); 

Histogenics Corporation, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of
Massachusetts), with principal offices at 830 Winter Street, 3rd floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (“Histogenics”); 

WITNESSETH 

WHEREAS, Angiotech Biomaterials Corp. (“Biomaterials”), Angiodevice and Histogenics entered into that certain License
Agreement, effective as of May 12, 2005, pursuant to which biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacturer and use of CT3
(the “Original License Agreement”), a copy of which is attached hereto; 
 WHEREAS effective as of November 4,
2005, all of the assets of Biomaterials were sold to Angiotech US and Biomaterials was wound up; 
 WHEREAS, in connection with such
sale of assets, Biomaterials assigned the Original License Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Original License Agreement as if it were the original party thereto; 

WHEREAS, Angiotech US, Angiodevice and Histogenics entered into an Amendment to License Agreement, dated as of August 31, 2007, a
Second Amendment to License Agreement, dated as of January 1, 2008, a Third Amendment to License Agreement, dated as of April 15, 2008, a Fourth Amendment to License Agreement, dated as of November 1, 2008, a Fifth Amendment to
License Agreement, dated as of August 6, 2010, and a Reinstatement Agreement and Sixth Amendment to License Agreement, dated as of February 8, 2011 (the “Reinstatement”); and the Original License Agreement, as amended by
the foregoing amendments (the “Agreement”); 

  
 - 1 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 WHEREAS, Angiodevice, Angiotech US and Histogenics entered into the Reinstatement for
the purpose of reinstating the Agreement and setting forth the conditions for doing so; 
 WHEREAS, Angiotech US, Angiodevice and
Histogenics have determined that it is in their best interests to enter into this Seventh Amendment to amend the date by which Histogenics must have closed a Qualified Financing as set forth in Section 2.1 of the Reinstatement; 

WHEREAS, **** 

NOW, THEREFORE, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows: 
 1.
Definitions. Capitalized terms used in this Seventh Amendment shall have the meaning given to them in the Agreement unless they are otherwise defined herein. 

2. Amendment of Section 2.1. Section 2.1 of the Reinstatement is hereby amended to read as follows: 

2.1 Angiodevice, Angiotech US and Histogenics acknowledge that the Agreement shall terminate as of the Termination Date. However, if no later
than **** (except as to clause (a), below, for which the date shall be no later than ****), Histogenics has fulfilled all of the following: (a) closed a bona fide financing of Histogenics with net proceeds to Histogenics of at least ****
(the “Qualified Financing”); (b) paid to Angiotech one million dollars ($1,000,000) (the “Reinstatement Fee”); and (c) paid to Angiotech fifty thousand dollars ($50,000) (the “Annual Patent
Fee”); then on the date that Histogenics fulfills the requirements of the last of (a), (b) and (c) (the “Reinstatement Date”), the Termination Notice shall be treated as if it were never given, the Agreement shall
be deemed to have continuously been in full force and effect from the Termination Date to the Reinstatement Date, and the Agreement shall continue thereafter in accordance with its terms. 

3. Miscellaneous. 
 3.1 Entire
Agreement; Confirmation of Agreement. Except as specifically otherwise amended as set forth herein, the Agreement shall continue in full force and effect. 

3.2 Counterparts. This Seventh Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. Facsimile signatures of the parties hereto will have the same effect as original signatures. In making proof of this Seventh Amendment, it shall not be necessary to produce or account
for more than one such counterpart. 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 2 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the parties have caused this Seventh Amendment to be executed and
delivered by the respective duly authorized officers as of the date first set forth above. 
  

													
	ANGIOTECH PHARMACEUTICALS (US), INC.	 		 	ANGIODEVICE INTERNATIONAL GmbH
					
	By:	 	  
	 		 	By:	 	  

		 	Name:	 	K. Thomas Bailey	 		 		 	Name:	 	David D. McMasters
		 	Title:	 	President	 		 		 	Title:	 	Managing Director
		 	Date:	 		 		 		 	Date:	 	
					
	HISTOGENICS CORPORATION	 		 		 		 	
						
	By:	 	 /s/ Richard C. Vaillant
	 		 		 		 	
		 	Name:	 	Richard C. Vaillant	 		 		 		 	
		 	Title:	 	CFO	 		 		 		 	
		 	Date:	 	3-24-11	 		 		 		 	

  
 - 3 -EX-10.18

 Exhibit 10.18 

CONFIDENTIAL TREATMENT REQUESTED 

EIGHTH AMENDMENT 
 TO

 LICENSE AGREEMENT 

THIS EIGHTH AMENDMENT TO LICENSE AGREEMENT (this “Eighth Amendment”), effective June 29, 2012, is by and among:

 Angiotech Pharmaceuticals (US), Inc., a corporation organized and existing under the laws of the State of Washington, with
principal offices at North Bend, WA (“Angiotech US”); 
 Angiodevice International GmbH, a corporation organized and
existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (“Angiodevice” and, together with Angiotech US, the “Licensor”); and 

Histogenics Corporation, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of
Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (“Histogenics”). 

WITNESSETH 

WHEREAS, Angiotech Biomaterials Corp. (“Biomaterials”), Angiodevice and Histogenics entered into that certain License
Agreement, effective as of May 12, 2005, pursuant to which Biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3
(the “Original License Agreement”); 
 WHEREAS, effective as of November 4, 2005, all of the assets of
Biomaterials were sold to Angiotech US and Biomaterials was wound up and in connection with such sale of assets, Biomaterials assigned the Original License Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials
under the Original License Agreement as if it were the original party thereto; 
 WHEREAS, the Licensor and Histogenics entered into
that certain Amendment to License Agreement, dated as of August 31, 2007, that certain Second Amendment to License Agreement, dated as of January 1, 2008, that certain Third Amendment to License Agreement, dated as of April 15, 2008,
that certain Fourth Amendment to. License Agreement, dated as of November 1, 2008, that certain Fifth Amendment to License Agreement, dated as of August 6, 2010, that certain Reinstatement Agreement and Sixth Amendment to License
Agreement, dated as of February 8, 2011, and that certain Seventh Amendment, effective as of March 31, 2011 (the Original License Agreement, as amended by the foregoing amendments, shall be referred to herein as the
“Agreement”); 
 WHEREAS, Section 4.1 of the Original License Agreement contained a diligence obligation
requiring Histogenics to **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 ****; 

WHEREAS, Histogenics desires to amend the Agreement to remove the provision requiring ****; 

WHEREAS, Angiotech US, Angiodevice, and Histogenics have determined that it is in their best interests to amend the provisions
regarding diligence obligations in Section 4.1 of the Agreement; 
 NOW, THEREFORE, in consideration of the mutual
promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows: 

 

	1.	Amendment. 

 1.1 Section 4.1 of the Agreement is hereby amended and restated in its
entirety to state as follows: 
 “4.1 Diligence Obligations. It is understood and acknowledged that part of the consideration for
this License is Histogenics’s intention to bring one or more Eligible Products to market through a program for exploitation of the Licensed Technology and, once commercialized, thereafter to continue active, diligent marketing and sales efforts
for Eligible Products throughout the life of this Agreement. 
  

	2.	Miscellaneous 

 2.1 Entire Agreement; Confirmation of Agreement. Except as
specifically otherwise amended as set forth herein, the Agreement shall continue in full force and effect. 
 2.2 Counterparts. This
Eighth Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures of the parties hereto will have the same effect as
original signatures. In making proof of this Eighth Amendment, it shall not be necessary to produce or account for more than one such counterpart. 

[Signature Page Follows] 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 2 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the parties have caused this Eighth Amendment to be executed and
delivered by the respective duly authorized officers as of the date set forth above. 
  

													
	ANGIOTECH PHARMACEUTICALS (US), INC.	 		 	ANGIODEVICE INTERNATIONAL GmbH
					
	By:	 	/s/ Tammy Neske	 		 	By:	 	/s/ K. Thomas Bailey
		 	Name:	 	 Tammy Neske
	 		 		 	Name:	 	K. Thomas Bailey
		 	Title:	 	Authorized Signatory	 		 		 	Title:	 	Director
		 	Date:	 	June 29, 2012	 		 		 	Date:	 	June 29, 2012
					
	HISTOGENICS CORPORATION	 		 		 		 	
						
	By:	 	 /s/ Patrick O’Donnell
	 		 		 		 	
		 	Name:	 	Patrick O’Donnell	 		 		 		 	
		 	Title:	 	President & CEO	 		 		 		 	
		 	Date:	 	June 29, 2012	 		 		 		 	

  
 - 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]